Season 4 of Surfing The NASH Tsunami

S4-50.7 - Wrapping up 2023 - An Interview with Donna Cryer

S4-50.7 – Wrapping up 2023 – An Interview with Donna Cryer

Global Liver Institute Founder and CEO Donna Cryer joins Louise Campbell and Roger Green to discuss her personal challenges during the last part of 2023, the growing strength of the Global Liver Institute and the challenges facing GLI and the entire community in 2024.

S4-50.4 - Wrapping Up 2023 - An Interview with Dean Tai

S4-50.4 – Wrapping Up 2023 – An Interview with Dean Tai

HistoIndex Chief Scientific Officer Dean Tai joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss how advances in MASLD artificial intelligence will spur knowledge, insight and innovation in drug development and NITs.

S4-E49-6-NITs-TLM-2022

S4-49.6 – Conversations from the Vault: NITs at TLM 2022

This Vault conversation stems from the wrap-up to TLM2022. In the episode, the panel (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Ken Cusi, Wayne Eskridge and Roger Green) addresses several topics from the program. This one focuses largely on NITs.

S4-E48.1 - Reviewing TLM 2023 Part One: A Discussion With Zobair Younossi

S4-E48.1 – Reviewing TLM 2023 Part One: A Discussion With Zobair Younossi

Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.

S4-E47 - Previewing The Liver Meeting 2023: Abstracts of Interest Share Episode Stats

S4-E47 – Previewing The Liver Meeting 2023: Abstracts of Interest Share Episode Stats

Previewing The Liver Meeting 2023: Last week’s posting consisted of 1:1 interviews with four KOL from different spheres, each talking with Roger Green about what they are looking forward to seeing at this week’s The Liver Meeting 2023. This week, two of those KOLs, co-host Jörn Schattenberg and hepatology KOL Naim Alkhouri, join Roger and co-host Louise Campbell, FRCP, in a free-wheeling review of key abstracts that will be presented at TLM2023.

S4-E46.4 - The Liver Meeting 2023: Updates with Key Opinion Leader, Scott Isaacs MM

S4-E46.4 – The Liver Meeting 2023: Updates with Key Opinion Leader, Scott Isaacs MM

This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this conversation, Key Opinion Leader, Scott Isaacs, joins to discuss this highly anticipated event as well as offer a glimpse into his current work and research interests.

S4-E46.3 - The Liver Meeting 2023: Updates with Key Opinion Leader, Naim Alkhouri

S4-E46.3 – The Liver Meeting 2023: Updates with Key Opinion Leader, Naim Alkhouri

This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this conversation, friend of the podcast, Naim Alkhouri, joins to discuss this highly anticipated event as well as offer a glimpse into his current work and research interests.

S4-E46.2 - Anticipating TLM 2023 with Michael Betel

S4-E46.2 – Anticipating TLM 2023 with Michael Betel

This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about anticipations around the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this session, President of the Fatty Liver Alliance, Michael Betel,  joins to discuss this highly anticipated event, plus some additional key ideas around patient advocacy.

S4-E46.1 - The Liver Meeting 2023: Updates with Key Opinion Leader, Jörn Schattenberg

S4-E46.1 – The Liver Meeting 2023: Updates with Key Opinion Leader, Jörn Schattenberg

This week on Surfing NASH, host Roger Green embarks on a series of one on one interviews with KOLs and patient advocates to talk about the Liver Meeting 2023 (held in Boston from November 10 – 14) and much more. In this first conversation, Jörn Schattenberg joins to discuss this highly anticipated event as well as offer a glimpse into his current work and research interests.

S4-E45.2 - Hepatology Under Air Raids

S4-E45.2 – Hepatology Under Air Raids

In continuation of the Surfing NASH interview series, Roger Green talks to Professor Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center.

S4-E45.1 - Meeting Professor Oren Shibolet

S4-E45.1 – Meeting Professor Oren Shibolet

In continuation of the Surfing NASH interview series, this week Roger Green talks to Professor Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center.

S4-E44.5 - From the Vault: Creating An Early Diagnosis NASH Decision Model

S4-E44.5 – From the Vault: Creating An Early Diagnosis NASH Decision Model

In this conversation, Ian Rowe describes the factors that motivated him and Richard Parker to build a decision model focusing on early NASH diagnosis. He identifies three data points demonstrating how severely NASH stakeholders need a better early diagnosis paradigm and then describes the five diagnostic strategies his model will test.

S4-E44.4 - How does MASH and MASLD differ in women compared to men?

S4-E44.4 – How does MASH and MASLD differ in women compared to men?

This final conversation covers the other paper discussed in the episoe at large, a literature review looking at how MASH and MASLD might differ in women compared to men. Roberta starts by noting the gap in literature about gender differences in MASH studies, and that women appear represented in most clinical trials.

S4-E44.3 - Roberta Forlano on Different Challenges for Different Patient Populations

S4-E44.3 – Roberta Forlano on Different Challenges for Different Patient Populations

This conversation starts with Roger asking Roberta to describe the demographics of the population in the northwest London region where the study of interest was done. Roberta comments on the robust diversity of the population, after which Louise amplifies this point by noting the large number of Arabic and South Asian patients in the study population.

S4-E44.2 - Investigating False Negative Screening Rates

S4-E44.2 – Investigating False Negative Screening Rates

This conversation starts with your Jörn returning to a key point from Roberta’s paper around a 38% false negative rate for FIB-4 screening. Jörn notes that while this feels like a high rate for false negatives, it might not present as much of a diagnostic challenge if treaters repeat the screening every 2 to 3 years.

S4-E44 - Screening Strategies for Gender-Based SLD Challenges

S4-E44 – Screening Strategies for Gender-Based SLD Challenges

In a recent SurfingNASH episode, Dr. Roberta Forlano, celebrated for her hepatology research and EASL Juan Rodes PhD Fellowship, delves into critical aspects of NAFLD, from screening strategies in primary care to non-invasive markers, alongside experts Jörn Schattenberg, Louise Campbell, and Roger Green. The discussions, centered on screening strategies for gender-specific SLD challenges, also showcase Roberta’s team’s notable contributions to the SLD Summit. A must-listen for those interested in advanced hepatology topics and research developments.

S4-E43.6 - Career Advice on Academia vs Corporate Life

S4-E43.6 – Career Advice on Academia vs Corporate Life

This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.

S4-E43.5 - Corporate life vs academia: which is right for who?

S4-E43.5 – Corporate life vs academia: which is right for who?

This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.

S4-E43.4 - Michelle Long on Academia vs Industry

S4-E43.4 – Michelle Long on Academia vs Industry

This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.

S4-E43.3 - Rachel Zayas on the Trajectory of and Intentionality Behind AGED Diagnostics

S4-E43.3 – Rachel Zayas on the Trajectory of and Intentionality Behind AGED Diagnostics

This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.

S4-E43.2 - CEO Rachel Zayas on Fundraising and Venture Competitions

S4-E43.2 – CEO Rachel Zayas on Fundraising and Venture Competitions

This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.

S3-E43.1 - Rachel Zayas on the Product Development Process of AGED Diagnostics

S3-E43.1 – Rachel Zayas on the Product Development Process of AGED Diagnostics

This week, SurfingNASH offers an episode comprising two seperate interviews which focus on stories around career trajectories, transitions and entrepreneurship. Host Roger Green talks with Rachel Zayas (AGED Diagnostics) and Michelle Long (Novo Nordisk) about their unique stories and creating new opportunities amidst a field with broadening but sometimes opaque horizons.

S4-E42.5 - Final Recap of the 2023 SLD Summit: Takeaways and Looking Forward

S4-E42.5 – Final Recap of the 2023 SLD Summit: Takeaways and Looking Forward

The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD. In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.

S4-E42.4 - Hannes Hagström on the Broad Aperture of the SLD Summit

S4-E42.4 – Hannes Hagström on the Broad Aperture of the SLD Summit

The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.

In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.

S4-E42.3 - Diving into Research from the EASL SLD Summit

S4-E42.3 – Diving into Research from the EASL SLD Summit

The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.

In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.

S4-E42.2 - MASH, MetALD and Alcoholic SLD: A Continuum?

S4-E42.2 – MASH, MetALD and Alcoholic SLD: A Continuum?

The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.

In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.

S4-E42.1 - Sven Francque on Organizing the EASL SLD Summit

S4-E42.1 – Sven Francque on Organizing the EASL SLD Summit

The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.

In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.

S4-42 - EASL SLD Summit 2023

S4-42 – EASL SLD Summit 2023

Surfing NASH reviews the 2023 EASL SLD Summit in two interview sessions with meeting faculty members Sven Francque and Hannes Hagström. Co-host Jörn Schattenberg joins both conversations as a fellow presenter while Louise Campbell and Roger Green inject thought-provoking questions and perspectives to elicit a succinct snapshot of the event for our listeners.

S4-41.6 - From the Vault: Highlights from Paris NASH 2021

S4-41.6 – From the Vault: Highlights from Paris NASH 2021

In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!

S4-41.3 - Laurent Castera on the FDA's NIT Workshop

S4-41.3 – Laurent Castera on the FDA’s NIT Workshop

In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. Laurent focuses on why this workshop is important within its context of being hosted by the FDA and what that means for researchers and stakeholders across the globe. He also dives into the complexities of hepatocellular ballooning and its potential impact on patients receiving NASH pharmacotherapy.

S4-41.1 - Naim Alkhouri on an NIT-based alternative path to conditional approval

S4-41.1 – Naim Alkhouri on an NIT-based alternative path to conditional approval

In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. Naim expands on ideas around an NIT-based alternative path to conditional approval as well as provides a general survey of how the workshop played out as he served as an expert panelist in Tuesday’s penultimate session.

S4-41 - Reviewing the FDA's NIT Workshop

S4-41 – Reviewing the FDA’s NIT Workshop

The Surfers are joined by Naim Alkhouri, Laurent Castera and Veronica Miller in three distinct interviews on the topic of the recent FDA workshop around NIT development and the future of the field.

S4-40.5 - Paris NASH Review: More Topics and Final Thoughts

S4-40.5 – Paris NASH Review: More Topics and Final Thoughts

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating final conversation which raises new and interesting topics covered at the event.

S4-40.4 - Challenges in Treating and Assessing Adequately

S4-40.4 – Challenges in Treating and Assessing Adequately

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a conversation around the complex challenges in adequately assessing and treating patients.

S4-40.3 - Which test is best for which patients?

S4-40.3 – Which test is best for which patients?

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. In this conversation, presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green to ask and answer questions surrounding the task of testing patients for optimized results under different scenarios.

S4-40.2 - Deeper Dive into the Landscape of NITs

S4-40.2 – Deeper Dive into the Landscape of NITs

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.

S4-40.1 - Liver as a Regenerative Organ and the Use and Limitations of NITs

S4-40.1 – Liver as a Regenerative Organ and the Use and Limitations of NITs

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.

S4-40 - Review of Paris NASH 2023

S4-40 – Review of Paris NASH 2023

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for an exciting episode that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. Surf on to learn much more from what always pans out to be an incredibly in-depth and insightful event.

S4-39.4 - MASEF: Where will we be in 2 years?

S4-39.4 – MASEF: Where will we be in 2 years?

Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This final session considers a few more populations who might benefit from such a test before the panelists field a final question that speculates what MASEF will look like 2 years from today.

S4-39.3 - MASEF: Next Steps and New Cohorts

S4-39.3 – MASEF: Next Steps and New Cohorts

Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This conversation considers applying the test to pediatric populations and the newly classified Met-ALD population (those with MASLD who consume greater amounts of alcohol per week). Additionally, the group considers what’s next for MESAF and how metabolomic tests are becoming commercially available in different countries.

S4-39.2 - MASEF: Cost Effectiveness and Application Settings

S4-39.2 – MASEF: Cost Effectiveness and Application Settings

In this conversation, Mazen Noureddin fields questions from Jörn Schattenberg, Louise Campbell and Roger Green around different application settings for the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The group discusses pros and cons of different approaches and speculate on challenges such as cost effectiveness and ease of use.

S4-39.1 - MASEF: Study Parameters and Notable Results

S4-39.1 – MASEF: Study Parameters and Notable Results

In this conversation, Mazen Noureddin introduces his recent work around serum identification of at-risk MASH and the recent paper he co-authored on the subject. He describes the aims of the study as well as provides a cogent background for why this work came to be and maintains its relevance.

S4-39 - The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

S4-39 – The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

Surfing NASH returns to its regular program with a fresh episode and some fascinating and progressive ideas on non-invasive testing with Mazen Noureddin. For this feature, Mazen talks about his recent work in serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) respond with their thoughts and varying perspectives.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud